超低分次全乳照射联合序贯瘤床加量的早期安全性:SHIFT二期试验
SHIFT是一项多中心单臂二期试验,评估早期乳腺癌保乳术后1.5周内完成超低分次全乳照射联合序贯瘤床加量的方案。217例患者中209例接受瘤床加量,6个月内≥2级急性毒性发生率为7.4%,无3级事件,中位随访28.3个月无严重毒性及复发转移或死亡。
要点
- 6个月内≥2级急性毒性仅7.4%,无3级事件。
- 中位随访28.3个月无严重毒性、局部复发、远处转移或死亡。
- 全乳26 Gy/5次联合瘤床10.4 Gy/2次方案耐受性良好。
核心结论
- 该整合超低分次放疗方案耐受性良好,急性毒性特征支持其有利的安全性。
研究设计与样本
- 多中心单臂二期试验,中国4家三级医院,纳入保乳术后浸润性乳腺癌(pT1-3, N0-1mic, M0)或导管原位癌患者,年龄≥18岁。
- 全乳照射26 Gy分5次5天完成,序贯瘤床加量10.4 Gy分2次2天由放疗医生决定,主要终点为放疗后6个月内≥2级急性放射性毒性(疲劳、皮炎、乳房疼痛)。
主要发现
- 2021年1月至2023年7月完成217例入组,其中209例接受瘤床加量。
- 放疗后6个月内,157例(72.4%)仅发生1级急性毒性,16例(7.4%)发生2级急性毒性,无3级事件,44例(20.3%)未报告毒性事件。
- 中位随访28.3个月,任何时间均未发现严重毒性,无局部区域复发、远处转移或死亡。
- 剂量学分析显示所有中心方案依从性高。
关键数值与推荐
- 全乳照射剂量26 Gy分5次,序贯瘤床加量10.4 Gy分2次。
- 主要终点为6个月内≥2级急性放射性毒性发生率。
临床怎么用
- 对于符合条件的早期乳腺癌保乳术后患者,可考虑采用1.5周内完成全乳照射联合序贯瘤床加量的超低分次方案。
局限性
- 单臂设计,无对照组。
- 随访时间尚短,长期晚反应和疗效仍在随访中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The multicenter, single-arm, phase 2 SHIFT trial evaluated an ultra-hypofractionated radiation therapy regimen that completes both whole breast irradiation and a sequential tumor bed boost within 1.5 weeks, with the primary endpoint of acute toxicity. METHODS AND MATERIALS: Patients at 4 tertiary hospitals in China aged 18 years or above with invasive breast carcinoma (pT1-3, N0-1mic, M0) or ductal carcinoma in situ after BCS were eligible. All enrolled patients underwent whole breast irradiation of 26 Gy in 5 fractions over 5 days. A sequential tumor bed boost of 10.4 Gy in 2 fractions over 2 days was at the discretion of the radiation oncologist. The primary endpoint was the incidence of grade ≥2 acute radiation-induced toxicity within 6 months after RT, including fatigue, dermatitis, and breast pain. This trial is registered at ClinicalTrials.gov (NCT04926766). RESULTS: Between January 2021 and July 2023, recruitment of 217 patients has been completed, of whom 209 received tumor bed boost. Within 6 months after RT, 157 (72.4%) patients experienced G1 acute toxicity only, 16 (7.4%) patients experienced G2 acute toxicity, with no G3 events observed. No toxicity event was reported in 44 (20.3%) patients. At a median follow-up of 28.3 months, no severe toxicities were found in any patient at any time during follow-up. No locoregional recurrence, distant metastasis, or death occurred. Dosimetric analysis demonstrated high protocol compliance across all centers. CONCLUSIONS: The integrated ultra-hypofractionated radiation therapy regimen is well-tolerated, with acute toxicity profiles confirming its favorable safety profile. Long-term follow-up is ongoing to assess late effects and efficacy.
引用
- Zheng SY, Huang JQ, Xie JR, et al. Early Safety of Ultra-Hypofractionated Whole Breast Irradiation and Sequential Tumor Bed Boost for Early Breast Cancer (SHIFT): A Multicenter, Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 41759682. doi:10.1016/j.ijrobp.2026.02.233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。